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Abstract
Background: Detecting change in health status over time and ascertaining meaningful changes are critical
elements when using health-related quality of life (HRQL) instruments to measure patient-centered outcomes. The
PedsQL™ Sickle Cell Disease module, a disease specific HRQL instrument, has previously been shown to be valid
and reliable. Our objectives were to determine the longitudinal validity of the PedsQL™ Sickle Cell Disease module
and the change in HRQL that is meaningful to patients.
Methods: An ancillary study was conducted utilizing a multi-center prospective trial design. Children ages 4–21
years with sickle cell disease admitted to the hospital for an acute painful vaso-oclusive crisis were eligible. Children
completed HRQL assessments at three time points (in the Emergency Department, one week post-discharge, and
at return to baseline (One to three months post-discharge). The primary outcome was change in HRQL score. Both
distribution (effect size, standard error of measurement (SEM)) and anchor (global change assessment) based methods
were used to determine the longitudinal validity and meaningful change in HRQL. Changes in HRQL meaningful to
patients were identified by anchoring the change scores to the patient’s perception of global improvement in pain.
Results: Moderate effect sizes (0.20–0.80) were determined for all domains except the Communication I and Cognitive
Fatigue domains. The value of 1 SEM varied from 3.8–14.6 across all domains. Over 50% of patients improved by at
least 1 SEM in Total HRQL score. A HRQL change score of 7–10 in the pain domains represented minimal perceived
improvement in HRQL and a HRQL change score of 18 or greater represented moderate to large improvement.
Conclusions: The PedsQL™ Sickle Cell Disease Module is responsive to changes in HRQL in patients experiencing acute
painful vaso-occlusive crises. The study data establish longitudinal validity and meaningful change parameters for the
PedsQL™ Sickle Cell Disease Module.
Trial Registration: ClinicalTrials.gov (study identifier: NCT01197417). Date of registration: 08/30/2010
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Background
With the use of valid and reliable measures of health-
related quality of life (HRQL), it has been well established
that many patients with sickle cell disease have significant
impairment in HRQL when in their baseline state of
health [1]. The ability of a HRQL instrument to detect
true change in health status over time (longitudinal
validity) and knowledge of what change is meaningful to
patients are both critical elements when using HRQL
instruments to measure this patient-centered outcome.
Recently the PedsQL™ Sickle Cell Disease module has
been shown to be a feasible, reliable, and valid disease
specific measure of HRQL [2]. However, the ability of this
instrument to detect change in patients with sickle
cell disease and knowing whether that change in
HRQL is meaningful have not been determined. Un-
derstanding whether a change in HRQL reflects a
meaningful change in health status for a patient is
critical to support use of the measure in clinical trials
and in the clinical care of patients.
The objectives of this paper are to determine the
longitudinal validity of the PedsQL™ Sickle Cell
Disease module and the change in HRQL that is
meaningful. We hypothesized that the module would
be responsive and would detect improvement in
HRQL that was meaningful in patients who were ex-
periencing an acute vaso-occlusive painful episode,
specifically in the relevant domain of pain. Our
secondary objectives were to determine the respon-
siveness of the PedsQL™ Generic Core Scales and Multi-
dimensional Fatigue Module in these patients. We
hypothesized that these instruments would detect change
in the physical functioning and general fatigue domains.
Methods
Study setting and subjects
This study was conducted as an ancillary study within a
multi-center randomized, double-blind, placebo con-
trolled trial from December, 2010 to March, 2014 [3].
Eight clinical centers in the United States that are part
of the Pediatric Emergency Care Applied Research Net-
work (PECARN) participated in the study of patients
ages 4–21 years who had sickle cell disease, specifically
hemoglobin SS disease or hemoglobin Sβ0 thalassemia
and who presented to the emergency department with a
painful vaso-occlusive crisis. Patients were eligible for
this HRQL study if they were admitted to the hospital
for management of a painful vaso-occlusive crisis,
enrolled in the parent trial, and completed HRQL
measures for at least two of the HRQL measurement
time points [3, 4]. For this ancillary HRQL study, all pa-
tients were combined into a single cohort of youth ages
4–21 years with hemoglobin SS or hemoglobin Sβ0 tha-
lassemia to allow for examination of HRQL change over
time because there were no differences between placebo
and treatment groups in the primary (clinical endpoints)
and secondary outcomes (HRQL) of the clinical trial.
Details describing HRQL between placebo and treatment
groups in the clinical trial are published elsewhere [3, 4].
The institutional review boards of each clinical center
approved the study and consent for participation was
obtained from all subjects and their parents. The study
was registered at ClinicalTrials.gov (study identifier:
NCT01197417).
Measurements
Demographic and medical information was obtained on
all patients through parent report and review of the
child’s medical record.
The Peds QL™ Sickle Cell Disease Module is a 43
item module that encompasses nine scales including
pain [2]. The module uses a 5-point Likert response
scale (0 = never a problem to 4 = almost always a
problem) that is reverse scored and transformed to a
0–100 scale (0 = 100, 1 = 75, etc.) so that a higher
score indicates better HRQL. The Total Score and the
scale scores are calculated by summing the items and
dividing by the number of items answered. Per the
developer’s instructions for scoring, at least 50% of
the items in a scale must be answered to compute a
scale score. The module has parallel reports for
parent proxy (age ≥ 2 years) and child self report
(age ≥ 5 years). For children ages 5–7 years the
module was completed with the help of the research
coordinator using a 3 point Likert scale as recom-
mended by the PedsQL™ Administration Guidelines.
The PedsQL™ Generic Core Scale is a 23 item mod-
ule that encompasses 4 scales. Its response scale and
scoring are similar to the PedsQL™ Sickle Cell Disease
module. The generic module also has two summary
scores, Physical Health Summary (same as Physical
Functioning Scale) and Psychosocial Health Summary
(sum of items answered in the emotional, social, and
school functioning scales divided by total number of
items answered) [5]. The PedsQL™ Multidimensional
Fatigue Scale is an 18 item measure that includes
three scales that measure different aspects of fatigue.
The scales are scored similarly to the Peds QL™ Sickle
Cell Disease Module scales [5].
Procedure
The HRQL measures were completed in paper form or
by report over the phone by both the parent and child at
three time points in this study 1) in the Emergency
Department after the decision to admit the patient was
made, 2) by phone one week post hospital discharge and
3) One to three months post discharge at a follow-up
clinic visit.
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To determine the patient’s perception of their improve-
ment, at the one week post hospital discharge assessment,
children were also asked to report how much they per-
ceived their pain had improved in the week following hos-
pital discharge via a global assessment of change question.
Analyses
Demographic and clinical characteristics of the cohort
were calculated using descriptive statistics. Longitudinal
validity was calculated using two distribution-based
methods and an anchor-based method. Distribution based
methods rely solely on statistics and do not account for
the patient’s perception of clinical change. An anchor
based method takes into account an expected meaningful
change that is then anchored to the change in HRQL
score. Lastly, to determine statistical significance of
change in HRQL over time, a linear mixed-effects model
was utilized. This multi-pronged approach for longitudinal
validity has been recommended in the literature [6].
Analyses were performed using SAS Version 9.3 (SAS
Institute, Cary, NC).
Distribution-based methods to support responsiveness
For the distribution-based methods, the effect size and the
standard error of measurement (SEM) were calculated. The
effect size was calculated to determine the magnitude of the
group differences for the two follow-up time points as fol-
lows: the mean change in HRQL scores between 1) one
week post discharge from the hospital and Emergency De-
partment divided by the standard deviation of the scores
from the Emergency Department and 2) One to three
months post hospital discharge and Emergency Department
divided by the standard deviation of the scores from the
Emergency Department. Using Cohen’s statistics, an effect
size of 0.2 is small, 0.5 is moderate, and >0.8 is large [7].
The SEM was used to determine what an important
change in score is for an individual and was calculated




where σ is the standard deviation of the baseline HRQL
score and α is the reliability (Cronbach’s alpha) of the
measure. The SEM represents the within-person variabil-
ity over time. One SEM is an estimate of a significant
change that has been shown repeatedly in prior research
to correspond to an anchor-based change threshold for an
individual, supporting responsiveness, in HRQL [8, 9].
Anchor-based methods to support meaningful change in
HRQL
Global assessment of change
For the anchor-based assessment, an anchor to pain was
used at one week post discharge to anchor whether the
change in HRQL was meaningful to patients. Specifically,
patient’s completed the following global assessment of
change in pain question: “Since you left the hospital, how
has your pain been?” Patients self reported their response
as: “No pain since discharge”, “Much better”, “A little bet-
ter”, “The same”, “A little worse”, Much worse”. Parents
provided proxy reported responses to the same global
assessment of change in pain question. This anchor was
chosen as it is relevant to patients, measures their
improvement in pain globally, and is interpretable [10].
Mean change in HRQL scores for the Total scores for
all three PedsQL™ measures and for the scores from the
pain scales of the disease specific measure were deter-
mined for the following collapsed categories of global as-
sessment of change in pain: “No pain since discharge”,
“Much better”, “A little better”, and “The same or worse”.
The categories of “The same, A little worse, and Much
worse” were combined as worse pain was expected to be a
rare occurence in this study setting. An anchor specific to
the remaining PedsQL™ HRQL scales (for example the
Emotional scale) were not assessed as part of this study.
A mean change in HRQL score that fell into the
category of “A little better” was considered the mini-
mum change that was meaningful. A mean change in
HRQL score that fell into the categories of “Much
better” and “No pain since discharge” were considered
moderate to large meaningful changes in HRQL.
A Spearman rank correlation coefficient was calculated
to assess the relationship between the clinical anchor
(global assessment of change question) and the target
HRQL domain.
Multivariable model to analyze HRQL over time
A linear mixed-effects multivariable model was used to
analyze the impact of age, hydroxyurea use, study site,
gender, and disease severity on HRQL (child self-report
total HRQL) over time (Emergency Department and 1-
week post-discharge). HRQL at 1–3 months was consi-
dered the baseline HRQL and included as a covariate. A
random intercept was included for subject, as well as a
random term for change in score between Emergency
Department and one-week follow-up. Age, measured in
years, was selected as a covariate because older children
experience more frequent acute sickle cell pain crises
and have longer length of hospital stay. Patient-reported
hydroxyurea within three months of admission was in-
cluded to examine the potential it may have to moderate
HRQL during an acute sickle cell pain crisis. Because
severity of sickle cell disease, study site, and gender
could also affect HRQL, these variables were also in-
cluded in the model. Children were classified as having
severe disease if they had a history of acute chest
syndrome and/or 3 or more hospitalizations for acute
sickle cell pain events in the prior 3 years consistent
with criteria we have used in the past [2, 11, 12]. All
others were classified as having mild disease. Total
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scores from three measures of HRQL were each consid-
ered as an outcome in separate models: the PedsQL™
Sickle Cell Disease, the PedsQL™ Multidimensional Fa-
tigue Scale score, and the PedsQL™ Generic Core Scale.
Cumulative distribution curves
In accordance with what has been recommended by
others [13, 14] and to make the data more meaningful to
clinicians, cumulative distribution function graphs were
used to illustrate change in HRQL from Emergency De-
partment presentation to one week follow-up for the
total HRQL scores for each measure and for each of the
three pain scales on the Sickle Cell Disease Module
(Pain Impact, Pain and Hurt, Pain Management scales).
Cumulative distribution curves present the full spectrum
of change for the study population and allow for varied
change thresholds or responder thresholds to be deter-
mined from these graphs [13].
Results
A total of 187 patients (Table 1) were enrolled in the
study. Ninety-four percent of patients were black and
4% were Latino. Eighty-nine percent had either been
hospitalized 3 or more times in the last 3 years and/or
had a history of acute chest syndrome constituting a
population with more severe disease. Details on the pro-
portion of patients with missing HRQL are provided in
the Additional file 1: Tables S1, S2 and S3. Overall,
HRQL scores were able to be calculated for over 80% of
the patients for each time point. Approximately 20% of
patients had missing global change in pain data.
Distribution based methods
Effect sizes support responsiveness to change (longitudinal
validity)
At the one week post discharge and one to three months
post discharge times points, the PedsQL™ Sickle Cell
Disease module was responsive to change (Table 2) in all
scales but the Worry II and Communication I scale. The
effect size was 0.74 and 0.70 for the Total Score at the
two follow up time points respectively supporting
moderate responsiveness to change.
The PedsQL™ Generic Core Scale and the PedsQL™
Multidimensional Fatigue Scale also had effect sizes
representing a small to moderate response to change in
all scales except for the cognitive fatigue domain for the
one to three month follow up time point.
For the parent proxy measures, effect sizes were small
to large. All scales of the proxy report of the PedsQL™
Sickle Cell Disease Module, Generic Core Scales, and
Multidimensional Fatigue Scales were responsive to
change except the Cognitive Fatigue scale (Additional
file 1: Table S4).
Standard error of measurement
The SEM scores were stable and similar at one week
and one to three months post discharge (Table 3). The
SEM for the Total Scores on all three of the HRQL
modules supports a change of 4–6 as a significant HRQL
change. For the scales within each module, a change of
7–15 supports a relevant change in HRQL scores. Fifty-
five to 66% of patients improved by one SEM or more in
Total Scores in this study supporting the responsiveness
of the measures for use during and after an acute painful
crisis. Over 50% of patients improved in the three pain
scales (Pain and Hurt, Pain Impact, and Pain Manage-
ment) of the sickle cell disease specific module. The least
improvement was in the Communication I domain (33%
one week post discharge and 30% one to three months
post discharge) of the disease specific module and in the
School Functioning (40% one week post discharge and
36% one to three months post discharge) domain of the
generic module.
For the parent proxy measures, a smaller change of 3–
4.5 in the total HRQL scores supports a relevant HRQL
change. For the scales within each module, a change of
5–12 supports a relevant change in HRQL scores.




Hgb SS 174 (93%)
Hgb Sβo 13 (7%)
Age, mean (sd) 13.5 (4.5)
Age group
4–11 years 74 (40%)
12–21 years 113 (60%)
Sex
Female 94 (50%)
Treated with hydroxyurea within 3 months
prior to randomization
114 (61%)
History of acute chest syndrome 143 (76%)







≥ 6 63 (34%)
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Anchor based method-Clinical change at one week
post-discharge
PedsQL™ Sickle Cell Disease Module
The correlation coefficients between the global assess-
ment of change in pain scores (anchor) and the HRQL
Total scores (Sickle cell disease Total, Fatigue Total, and
Generic Total. Pain and Hurt, Pain Impact, and Pain
Management HRQL scores) ranged from 0.33–0.56
supporting the relevance of the anchor.
Examining change in HRQL scores for the pain scales
(Pain and Hurt, Pain Impact, and Pain Management)
with the anchor, the HRQL change score increased with
each category of reported pain improvement (Table 4).
Focusing on the change of “A little better” to represent
the minimal patient reported improvement that supports
a clinical change, the change in HRQL scores ranged
from 7.5 to 10 for the three pain scales. This change is
essentially the same change found using the SEM. A
moderate to large improvement where a patient reported
a change of “Much better” was reflected in a change in
HRQL score of greater than 18 for the pain scales.
Examining the change in HRQL scores for the Total
HRQL scores for each measure, a minimal improvement
perceived by the patient as “a little better” is reflected as
a change in HRQL score ranging from 4.8 (Fatigue Total
score) to 9.5 (Generic Core Total score). These change
scores are similar to the change score found when appl-
ying the SEM method.
For the parent proxy measures, higher change scores
corresponded with improvement reported by the patient
as “a little better” and “much better” for the sickle cell
disease measure (Additional file 1: Table S6). For the fa-
tigue and generic measures, the change in parent proxy
HRQL scores were similar to the sickle cell disease
measure for the different anchor categories.
Multivariable model: age, hydroxyurea use, site, gender and
disease severity were not associated with improved HRQL
over time
In the linear mixed-effects model, age, hydroxyurea use,
site, gender, and disease severity were not significantly
associated with change in HRQL (Table 5). HRQL did
Table 2 Child self report health-related quality of life: effect sizes
ED Visit 1 Week 1–3 Months
Domain N Mean (SD) N Mean Effect Size N Mean Effect Size
Sickle cell disease module
Total Score 166 48.3 (15.87) 139 59.4 0.74 153 59.9 0.70
Pain and Hurt 165 49.8 (18.89) 137 66.6 0.91 152 62.7 0.66
Pain Impact 165 33.3 (19.53) 139 48.3 0.84 151 49.8 0.78
Pain Management
and Control
163 41.8 (28.24) 137 54.3 0.45 151 52.3 0.37
Worry I 165 48.7 (23.75) 137 56.1 0.34 151 62.5 0.54
Worry II 143 69.4 (28.17) 120 74.8 0.23 130 75.2 0.19
Emotions 164 47.5 (34.51) 138 58.6 0.39 152 61.0 0.37
Treatment 163 55.7 (20.54) 137 60.6 0.27 151 61.0 0.27
Communication I 162 70.9 (27.55) 136 74.2 0.13 149 73.1 0.08
Communication II 158 45.0 (28.96) 133 56.3 0.42 144 59.1 0.52
Fatigue module
Total Score 157 53.8 (18.53) 134 61.0 0.41 144 62.1 0.47
General Fatigue 158 52.0 (22.20) 135 60.0 0.39 145 64.0 0.54
Sleep/Rest Fatigue 157 48.6 (20.65) 134 57.1 0.46 144 59.2 0.54
Cognitive Fatigue 155 60.3 (26.29) 132 65.2 0.20 142 63.2 0.13
Generic module
Total Score 154 59.2 (18.08) 132 67.2 0.49 141 67.7 0.47
Physical Summary 155 55.7 (23.98) 133 64.7 0.43 142 66.5 0.42
Psychosocial Summary 153 61.4 (18.07) 131 68.6 0.43 139 68.5 0.40
Emotional Functioning 153 60.5 (23.84) 131 70.2 0.43 140 71.4 0.45
Social Functioning 151 72.2 (22.00) 129 76.4 0.24 137 76.8 0.27
School Functioning 147 51.4 (22.55) 120 58.2 0.33 131 56.6 0.25
Effect sizes > or = 0.2 in bold are significant
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Table 3 Percentage of patients with improved HRQL by 1 standard error of measurement or more
PedsQL™ HRQL Score 1 week post discharge Steady state 1–3 months post-discharge
Child self-report N SEM Percentage with ≥1
SEM improvement
N SEM Percentage with ≥1
SEM improvement
Sickle cell disease module
Total Score 139 3.94 65.5 153 3.80 66.0
Pain and Hurt 137 7.43 62.8 152 7.88 55.9
Pain Impact 139 7.00 64.0 151 7.50 58.9
Pain Management
and Control
137 10.09 50.4 151 10.72 51.0
Worry I 137 9.74 47.4 151 9.68 60.3
Worry II 120 14.55 33.3 130 13.59 24.6
Emotions 138 12.89 40.6 152 14.03 42.8
Treatment 137 9.61 35.0 151 9.99 42.4
Communication I 136 12.27 33.1 149 11.49 30.2
Communication II 133 13.51 46.6 144 13.11 50.0
Fatigue module
Total Score 134 5.72 54.5 144 5.49 54.2
General Fatigue 135 8.17 55.6 145 8.28 56.6
Sleep/Rest Fatigue 134 9.53 45.5 144 9.46 45.8
Cognitive Fatigue 132 8.20 47.0 142 8.04 45.1
Generic module
Total Score 132 5.09 59.1 141 5.13 57.4
Physical Summary 133 8.07 53.4 142 8.03 54.2
Psychosocial Summary 131 6.28 55.0 139 6.39 51.8
Emotional Functioning 131 9.96 55.7 140 9.59 55.0
Social Functioning 129 9.62 42.6 137 9.33 44.5
School Functioning 120 10.22 40.0 131 11.09 35.9
Table 4 Mean change in PedsQL™ health-related quality of life child report scores from baseline to one week post discharge as
categorized by child’s perception of pain within the 7–10 days post discharge
Domain No pain since
discharge









PedsQL™ Sickle Cell Disease Module
Total Score 19 20.1 (12.2, 28.0) 59 15.7 (10.6, 20.7) 41 5.8 (1.3, 10.3) 15 7.0 (0.4, 13.6)
Pain and Hurt 18 28.7 (17.8, 39.6) 59 25.1 (18.2, 32.1) 40 7.5 (1.1, 13.9) 15 3.9 (−7.0, 14.7)
Pain Impact 19 33.1 (21.3, 44.9) 58 19.8 (11.7, 28.0) 42 9.1 (3.5, 14.7) 15 8.7 (1.7, 15.7)
Pain Management and Control 18 18.8 (0.8, 36.7) 58 18.8 (10.9, 26.6) 42 9.8 (−0.3, 20.0) 14 6.3 (−8.7, 21.2)
PedsQL™ Multidimensional Fatigue Scale
Total Score
18 10.8 (3.1, 18.5) 56 10.4 (5.2, 15.5) 41 4.8 (−0.8, 10.4) 14 0.1 (−10.0, 10.3)
PedsQL™ Generic Core Scales Total Score 18 9.5 (0.5, 18.6) 56 10.4 (5.4, 15.3) 39 9.5 (4.9, 14.2) 14 0.3 (−9.3, 9.9)
a95% Confidence interval
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significantly improve from the time of presentation to
the Emergency Department to one week post discharge
even after adjustment for these covariates. Interactions
between covariates and time were explored in other
models, but were not found to be significant. Specific-
ally, the change in HRQL over time is the same regard-
less of hydroxyurea use, age, hospital site, gender and
disease severity.
Distribution curves
The cumulative distribution curves which provide data
needed to pick a responder threshold are shown for the
Total HRQL score for each of the three measures in Figs.
1, 2 and 3 (Peds QL™ Sickle Cell Disease Module, the
PedsQL™ Multidimensional Fatigue Scale and the
PedsQL™ Generic Core Scales). In addition, Figs. 4, 5 and
6 show the cumulative distribution curves for the three
pain scales of the Peds QL™ Sickle Cell Disease Module.
Figure 1, for example, demonstrates that approximately
25% of patients had either no change in their total Sickle
Cell Disease HRQL or had worse HRQL at one week post
hospital discharge. In contrast, approximately 28% of pa-
tients had an improvement in total Sickle Cell Disease
HRQL by 20 or more points at one week post discharge.
See Additional file 2: Figures S1-S6 for parent proxy
cumulative distribution curves.
Discussion
The PedsQL™ Sickle Cell Disease Module is responsive
to expected functional changes over time in patients
with sickle cell disease experiencing acute painful vaso-
occlusive crises. Our findings support the longitudinal
validity of the PedsQL™ Sickle Cell Disease module. Spe-
cifically, the module is most responsive to change in the
areas of pain, worry and communication. The PedsQL™
Multidimensional Fatigue module and PedsQL™ Generic
Core scales were most responsive to change in general
fatigue, sleep/rest, emotional functioning and physical
functioning. Using both anchor and distribution based
methods, our results also support relevant change scores
for the module for patients experiencing acute painful
vaso-occlusive crises. Lastly, our multivariable analyses
confirm that patients with acute painful vaso-occlusive
crises who are hospitalized have significant impairment
in HRQL that improves in the week post discharge by
which time it is similar to a patient’s baseline state at
one to three months post discharge. This work provides
the evidence needed to use patient reported outcomes in
measuring treatment effectiveness in clinical trials and
when estimating sample sizes for these trials. Given that
patient reported outcomes are what patients usually care
about most, understanding meaningful change scores is
critical to patient centered care.
Table 5 Multivariate analysis: Parameter estimates for child































Fig. 1 Cumulative Distribution Curve for the Child Self Report PedsQL™ Sickle Cell Disease Total Score
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Our results indicate that the PedsQL™ Sickle Cell Dis-
ease module was responsive to changes over time for chil-
dren hospitalized and treated for acute vaso-occlusive
painful crises. This was true for all domains but Commu-
nication I domain. The Communication I domain asks
about communicating with health care providers and
wouldn’t be expected to change in this clinical setting over
the period of time patients were followed. In addition, the
PedsQL™ Multidimensional Fatigue scale was responsive
to changes in all but the Cognitive Fatigue domain at one
to three months post discharge. The Cognitive domain
addresses issues with memory and attention whereby the
General Fatigue and Sleep/Rest Fatigue domains focus on
sleep and being physically active. Thus, it is understand-
able why significant changes over time were seen in the
General Fatigue and Sleep/Rest Fatigue domains in this
setting of recovery from an acute vaso-occlusive painful
event. Lastly, the PedsQL™ Generic Core Scales were
responsive to changes in all domains. These findings sup-
port the ability of these measures to detect change over
time in patients with sickle cell disease who are experien-
cing acute vaso-occlusive crises.
Fig. 2 Cumulative Distribution Curve for the Child Self Report PedsQL™ Multidimensional Fatigue Scale Total Score
Fig. 3 Cumulative Distribution Curve for the Child Self Report PedsQL™ Generic Core Total Score
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Using a common and well accepted anchor approach,
[15] we found that mean HRQL changes in specific
HRQL domains that are less than 5–6 are likely not
perceptible changes that reflect improvement in children
recovering from acute painful vaso-occlusive crises. Fur-
thermore, patients who perceived being “much better”
had changes of 10–25 points in specific HRQL areas one
week post hospital discharge. These meaningful changes
in HRQL that we found using an anchor based approach
are supported by the distribution methods we applied
[16]. In addition, consistent with what has been de-
scribed prior, the SEM in our study was similar across
time points as it accounts for the variability of the data
[8, 9, 17].
Cumulative distribution curves allow one to see the
full spectrum of HRQL change and to determine the
threshold of change that is appropriate for future
research and in clinical care. This prevents one from
having to rely on what can be a more arbitrary change
threshold. This is important when studying pain given
the inherent variability in pain expression from person
to person. In our study, approximately 40% of patients
had a change score in Total Sickle Cell Disease HRQL of
5.8 (perceived by patients as a little better) or less at one
Fig. 4 Cumulative Distribution Curve for the Child Self Report PedsQL™ Sickle Cell Disease Pain Impact Score
Fig. 5 Cumulative Distribution Curve for the Child Self Report PedsQL™ Sickle Cell Disease Pain and Hurt Score
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week post discharge. Sixty-two percent of patients had a
change score in Total Sickle Cell Disease HRQL of 15.7
(perceived by patients as much better) or less. Thus, the
value of reporting the cumulative distribution curves al-
lows for comparison of HRQL change across thresholds.
In addition, this facilitates comparison across thresholds
to determine treatment impact. For example, the
percentage of patients who have a change of at least the
minimum can be compared across different treatment
groups to determine the effectiveness of therapy on
patient reported outcomes.
It is important to remember that meaningful change
in HRQL varies by population and context. Our study
is limited to patients with sickle cell disease who were
hospitalized with acute painful vaso-occlusive crises
and may not be generalizable to all patients such as
to those who experience chronic pain. Further work
is needed to determine if the PedsQL™ Sickle Cell
Disease module is responsive to changes in patient
reported well being in other settings. For example, it
is unknown if the measure would detect changes in
the well being of patients treating painful events at
home. In addition, this study used a global change in
pain question as the anchor for meaningful change in
HRQL. Although this is the most common method
used and is a valid anchor to use, there is the risk of
recall bias or response shift as patients are asked to
retrospectively report their change in health [10].
Additionally, this anchor is not relevant to a patient’s
changes in other HRQL domains such as the emotion
domain and further evidence is needed to determine
the meaningful change for these domains. Lastly,
there was a small subset of patients who reported
their pain was no better or worse than when they
were initially seen in the Emergency Department.
Despite this, as a group, these patients had improve-
ment in their Total Sickle Cell Disease HRQL score
reflecting most likely that the patients are improved
in other areas of functioning. When examining the
pain domains, the change in HRQL reflecting patients
who reported they were “a little better” one week
post discharge for both the Pain and Hurt and Pain
Management domains was 7.5 and 9.8 respectively. In
comparison, the change in HRQL reflecting patients
that were “the same or worse” was 3.9 for the Pain
and Hurt domain and 6.3 for the Pain Management
domain supporting a relevant change in HRQL for
these two domains.
Conclusions
In summary, our study provides the longitudinal validity
and meaningful change in HRQL scores for relevant do-
mains of the PedsQL Sickle Cell Disease module, the
PedsQL™ Multidimensional Fatigue scale, and PedsQL™
Generic Core Scales. These results are applicable to un-
derstanding the clinical use of HRQL measures to aid in
evaluating patients’ functioning over time and may also in-
form future clinical trial research to measure effectiveness
of interventions in children with sickle cell disease.
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